70035-75-5

Basic information

• Product Name: 7-BMAC
• Synonyms: 7-BMAC;(6R,7S)-7-[(Bromoacetyl)amino]-7-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid diphenylmethyl ester;(6R,7S)-7-[(BroMoacetyl)aMino]-7-Methoxy-3-[[(1-Methyl-1H-tetrazol-5-yl)thio]Methyl]-8-oxo-5-thia-1-
• CAS NO: 70035-75-5
• Molecular Formula: C₂₆H₂₅BrN₆O₅S₂
• Molecular Weight: 645.55
• Mol File: 70035-75-5.mol

Chemical Properties

• Appearance: /
• Density: 1.62
• Refractive Index: 1.726
• CAS DataBase Reference: 7-BMAC(CAS DataBase Reference)
• NIST Chemistry Reference: 7-BMAC(70035-75-5)
• EPA Substance Registry System: 7-BMAC(70035-75-5)

Safety Data

• Hazardous Substances Data: 70035-75-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
7-BMAC is used as a research compound for the development of treatments targeting memory and perception defects. Its agonistic action on the metabotropic glutamate receptor mGlu1 makes it a valuable tool in understanding the underlying mechanisms of neurological conditions and exploring potential therapeutic interventions.
Used in Neurological Condition Treatments:
7-BMAC is used as a potential therapeutic agent for neurological conditions such as Alzheimer's and Parkinson's. Its ability to control and alter the activity of glutamate receptors in the brain suggests that it could play a role in managing the symptoms and progression of these disorders, offering hope for more effective treatments in the future.

InChI:InChI=1/C26H25BrN6O5S2/c1-32-25(29-30-31-32)40-15-18-14-39-24-26(37-2,28-19(34)13-27)23(36)33(24)20(18)22(35)38-21(16-9-5-3-6-10-16)17-11-7-4-8-12-17/h3-12,21,24H,13-15H2,1-2H3,(H,28,34)/t24-,26+/m1/s1

Upstream product

• 56610-72-1 diphenylmethyl (6R,7S)-7-amino-7-methoxy-3-<<(1-methyl-1H-tetrazol-5-yl)thio>methyl>-Δ³-cephem-4-carboxylate 
• 598-21-0 2-Bromoacetyl bromide 
• 67-56-1 methanol 
• 67366-04-5 (6R-cis)-7-amino-3-<<(1-methyl-1H-tetrazol-5-yl)thio>methyl>-7-(methylthio)-8-oxo-5-thia-1-azabicyclo<4.2.0>oct-2-ene-2-carboxylic acid diphenylmethyl ester 
• 934703-42-1 C₂₆H₂₅BrN₆O₄S₃ 
• 83934-73-0 (R)-3-(1-Methyl-1H-tetrazol-5-ylsulfanylmethyl)-8-oxo-7-[2,2,3-trichloro-3-phenyl-prop-(E)-ylideneamino]-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester 
• 53090-86-1 (R)-7-Amino-3-(1-methyl-1H-tetrazol-5-ylsulfanylmethyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester 
• 83934-79-6 (S)-7-[(Z)-2-Chloro-3-phenyl-prop-2-en-(E)-ylideneamino]-7-methoxy-3-(1-methyl-1H-tetrazol-5-ylsulfanylmethyl)-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester 

Downstream Products

• 61807-78-1 7β-bromoacetamido-7α-methoxy-3-(1-methyltetrazol-5-yl)thiomethyl-Δ³-cephem-4-carboxylic acid 

Relevant articles and documents

Preparation method of cefotetan disodium

The invention discloses a preparation method of cefotetan disodium, comprising the following steps: (1) preparing a first intermediate; (2) separating by extraction; (3) preparing a second intermediate; (4) separating by crystallization; (5) preparing a c

Purification of béta-lactam products

Method for purifying 7α-methoxy-cephalosporins containing as impurity the corresponding 7α-methylthio analogue, which is transformed into its methoxy analogue by treatment with a halogenating agent in methanol.

PURIFICATION OF BETA-LACTAM PRODUCTS

Method for purifying 7α-methoxy-cephalosporins containing as impurity the corresponding 7α-methylthio analogue, which is transformed into its methoxy analogue by treatment with a halogenating agent in methanol. In this way the complete conversion of the s